62 related articles for article (PubMed ID: 30583881)
1. Minimal inhibitory concentration of omadacycline and doxycycline against bacterial isolates with known tetracycline resistance determinants.
Fluit AC; van Gorkum S; Vlooswijk J
Diagn Microbiol Infect Dis; 2019 May; 94(1):78-80. PubMed ID: 30583881
[TBL] [Abstract][Full Text] [Related]
2.
Pham J; Benefield RJ; Baker N; Lindblom S; Canfield N; Gomez CA; Fisher M
Antimicrob Agents Chemother; 2024 May; 68(5):e0168623. PubMed ID: 38534103
[TBL] [Abstract][Full Text] [Related]
3. Omadacycline in Vitro Activity Against a Molecularly Characterized Collection of Clinical Isolates with Known Tetracycline Resistance Mechanisms.
Am Health Drug Benefits; 2018 Dec; 11(9):489. PubMed ID: 32117530
[No Abstract] [Full Text] [Related]
4. Integrated Safety Summary of Omadacycline, a Novel Aminomethylcycline Antibiotic.
Am Health Drug Benefits; 2018 Dec; 11(9):489. PubMed ID: 32117531
[No Abstract] [Full Text] [Related]
5. Antimicrobial Activity of Omadacycline Tested against Clinical Bacterial Isolates from Hospitals in Mainland China, Hong Kong, and Taiwan: Results from the SENTRY Antimicrobial Surveillance Program (2013 to 2016).
Carvalhaes CG; Huband MD; Reinhart HH; Flamm RK; Sader HS
Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30617092
[TBL] [Abstract][Full Text] [Related]
6. New antibiotics for community-acquired pneumonia.
Kollef MH; Betthauser KD
Curr Opin Infect Dis; 2019 Apr; 32(2):169-175. PubMed ID: 30640820
[TBL] [Abstract][Full Text] [Related]
7. Omadacycline: A New Tetracycline Antibiotic.
Dougherty JA; Sucher AJ; Chahine EB; Shihadeh KC
Ann Pharmacother; 2019 May; 53(5):486-500. PubMed ID: 30917674
[TBL] [Abstract][Full Text] [Related]
8. Omadacycline for Acute Bacterial Skin and Skin-Structure Infections.
O'Riordan W; Green S; Overcash JS; Puljiz I; Metallidis S; Gardovskis J; Garrity-Ryan L; Das AF; Tzanis E; Eckburg PB; Manley A; Villano SA; Steenbergen JN; Loh E
N Engl J Med; 2019 Feb; 380(6):528-538. PubMed ID: 30726689
[TBL] [Abstract][Full Text] [Related]
9. Omadacycline: A Novel Oral and Intravenous Aminomethylcycline Antibiotic Agent.
Zhanel GG; Esquivel J; Zelenitsky S; Lawrence CK; Adam HJ; Golden A; Hink R; Berry L; Schweizer F; Zhanel MA; Bay D; Lagacé-Wiens PRS; Walkty AJ; Lynch JP; Karlowsky JA
Drugs; 2020 Feb; 80(3):285-313. PubMed ID: 31970713
[TBL] [Abstract][Full Text] [Related]
10. Omadacycline: A Modernized Tetracycline.
Gallagher JC
Clin Infect Dis; 2019 Aug; 69(Suppl 1):S1-S5. PubMed ID: 31367739
[TBL] [Abstract][Full Text] [Related]
11. The efficacy and safety of omadacycline in treatment of acute bacterial infection: A systemic review and meta-analysis of randomized controlled trials.
Lan SH; Chang SP; Lai CC; Lu LC; Chao CM
Medicine (Baltimore); 2019 Dec; 98(51):e18426. PubMed ID: 31861009
[TBL] [Abstract][Full Text] [Related]
12. Omadacycline: A Review of the Clinical Pharmacokinetics and Pharmacodynamics.
Rodvold KA; Burgos RM; Tan X; Pai MP
Clin Pharmacokinet; 2020 Apr; 59(4):409-425. PubMed ID: 31773505
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and Pharmacodynamics of Oral and Intravenous Omadacycline.
Rodvold KA; Pai MP
Clin Infect Dis; 2019 Aug; 69(Suppl 1):S16-S22. PubMed ID: 31367744
[TBL] [Abstract][Full Text] [Related]
14. Microbiology and Preclinical Review of Omadacycline.
Karlowsky JA; Steenbergen J; Zhanel GG
Clin Infect Dis; 2019 Aug; 69(Suppl 1):S6-S15. PubMed ID: 31367743
[TBL] [Abstract][Full Text] [Related]
15. Omadacycline for Acute Bacterial Skin and Skin Structure Infections.
Abrahamian FM; Sakoulas G; Tzanis E; Manley A; Steenbergen J; Das AF; Eckburg PB; McGovern PC
Clin Infect Dis; 2019 Aug; 69(Suppl 1):S23-S32. PubMed ID: 31367742
[TBL] [Abstract][Full Text] [Related]
16. Budget Impact of Omadacycline for the Treatment of Patients with Community-Acquired Bacterial Pneumonia in the United States from the Hospital Perspective.
LaPensee K; Mistry R; Lodise T
Am Health Drug Benefits; 2019 Feb; 12(1-Supplement 1):S1-S12. PubMed ID: 30996766
[TBL] [Abstract][Full Text] [Related]
17. Surveillance of omadacycline activity tested against clinical isolates from the United States and Europe: Results from the SENTRY Antimicrobial Surveillance Programme, 2017.
Huband MD; Pfaller MA; Shortridge D; Flamm RK
J Glob Antimicrob Resist; 2019 Dec; 19():56-63. PubMed ID: 30825698
[TBL] [Abstract][Full Text] [Related]
18. Omadacycline for Community-Acquired Bacterial Pneumonia.
Stets R; Popescu M; Gonong JR; Mitha I; Nseir W; Madej A; Kirsch C; Das AF; Garrity-Ryan L; Steenbergen JN; Manley A; Eckburg PB; Tzanis E; McGovern PC; Loh E
N Engl J Med; 2019 Feb; 380(6):517-527. PubMed ID: 30726692
[TBL] [Abstract][Full Text] [Related]
19. Omadacycline - The Newest Tetracycline.
Chambers HF
N Engl J Med; 2019 Feb; 380(6):588-589. PubMed ID: 30726683
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
